Research ArticleHIV

Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa

See allHide authors and affiliations

Science Translational Medicine  18 Sep 2019:
Vol. 11, Issue 510, eaax1880
DOI: 10.1126/scitranslmed.aax1880

Taking RV144 beyond Thailand

The RV144 vaccine trial in Thailand is the only HIV vaccine to show efficacy against HIV infection to date. Gray et al. designed the HVTN 097 trial to test this regimen in South Africa, where clade C HIV circulates; this clade is heterologous to the vaccine antigens. They intently examined immune protective responses previously identified in the RV144 trial and found that the vaccine seemed to be even more immunogenic in South Africans. CD4+ T cell responses were stronger and more common in HVTN 097, and the magnitude of protective antibody responses was greater compared to RV144. Their results indicate that the RV144 regimen or others like it could be protective in areas where HIV is endemic.

View Full Text

Stay Connected to Science Translational Medicine